Recently, SINOAFRICA MEDICINES AND HEALTH LTD received the approval document of plant drug registration issued by Uganda National Drug Authority, which approved Lianhua Qingwen capsule of Shijiazhuang Yiling Pharmaceutical Co., Ltd. to be registered in accordance with Ugandan plant drug standard. The relevant information is hereby announced as follows:
1.Basic information of registration in Uganda
Product Name: Lianhua Qingwen capsule
Dosage form: capsule
2.Other relevant information of drugs
Lianhua Qingwen products are the leading products of Shijiazhuang Yiling Pharmaceutical Co., Ltd., national essential drug list and national medical insurance catalogue (Class A), mainly used for the treatment of cold and influenza related diseases. Lianhua Qingwen products have been listed in the diagnosis and treatment program of cold and influenza related diseases by the National Health Commission and the State Administration of traditional Chinese medicine for many times. The novel coronavirus capsule was approved by the national health and Health Commission and the State Administration of traditional Chinese medicine in 2020. The recommended treatment for pneumonia is a new coronavirus infection (Trial version four / five / six / seven / eight). In April 12th, 2020, the novel coronavirus pneumonia was approved by the State Administration of drug administration, adding new indications of "new light and general type of coronavirus pneumonia" based on the original approval.
